Aclarion, Inc. ACON
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -69.13%
- 1 year
- -75.81%
- Market cap
- 4.09M
- Revenue (ttm)
- 53.95K
- EPS (ttm)
- -5.01
- Shares out
- 10.44M
- Forward P/E
- -0.24
- YTD return
- -69.13%
- 1-year return
- -75.81%
- 50-day average
- 0.1701
- 200-day average
- 0.250115
- Volume
- 19.56K
- Avg volume
- 35.13K
- Open
- 1.35
- Previous close
- 1.34
- Day's range
- 1.35 – 1.45
- 52-week range
- 1.34 – 9.36
- Beta
- 0.40
- Analysts
- Buy
- Price target
- 1.30 (-8.5%)
Key statistics
- Enterprise value
- 960.52K
- Price / sales
- 24.77
- Revenue growth
- -35.70%
- Free cash flow
- -3.94M
- Total cash
- 1.22M
- Total debt
- 777.09K
- Return on equity
- -714.18%
- Short % of float
- 4.28%
Fundamental scorecard
10 of 25 checks passed on ACON’s reported financials
10of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.18 | -0.15 | +0.03 | +16.67% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.15 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.44 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Maxim Group | down | Buy | Hold |
| Nov 27, 2024 | Ascendiant Capital | main | Buy | Buy |
| Aug 26, 2024 | Ascendiant Capital | main | Buy | Buy |
| Jul 29, 2024 | Ascendiant Capital | init | — | Buy |
About Aclarion, Inc.
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- aclarion.com
News
Your note
Sign in to keep a note on ACON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LORBIECKI JOHN PAUL | Chief Financial Officer | Purchase | Dec 28, 2022 | 22,404 |
| NESS BRENT | Chief Executive Officer | Purchase | Dec 28, 2022 | 19,500 |
| THRAMANN JEFFREY JOHN | Officer and Director | Purchase | Feb 15, 2023 | 1 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Captrust Financial Advisors | 2.05% | 214,029 | 27.39K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.47% | 49,301 | 6.31K | Sep 29, 2024 |
| UBS Group AG | 0.38% | 39,971 | 5.12K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.32% | 33,892 | 4.34K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.14% | 14,153 | 1.81K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.12% | 12,239 | 1.57K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.32% | 33,266 | 4.26K | Oct 30, 2024 |
